NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT03875820 2026-03-10FRAMEInstitute of Cancer Research, United KingdomPhase 1 Active not recruiting87 enrolled